Data Validation in Clinical Research: Confusing Rules Explained
In this webinar, we explore what you should do when rules fire during data validation…
CertaraApril 30, 2020
Applying decision analysis to drug development for COVID-19 & future pandemics
This blog discusses how decision analysis approaches can help drug developers to better decisions under…
CertaraApril 30, 2020
Getting started with in-house development: storyboarding
Introducing our three-part blog series on getting started with in-house development. In this series, we’re…
CertaraFebruary 21, 2020
The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?
This webinar will explain how pricing has evolved for the rare disease drug market and…
CertaraFebruary 19, 2020
Getting started with in-house development: how does it work?
Introducing our three-part blog series on getting started with in-house development. In this series, we’re…
CertaraFebruary 10, 2020
How to Demonstrate Virtual Bioequivalence for Complex Dermal Generic Drugs
This webinar will explain how Certara expanded its PBPK Simcyp Simulator to incorporate an extensive…
CertaraJanuary 24, 2020
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
CertaraJanuary 17, 2020
Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development
Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…
CertaraDecember 19, 2019
